Integral Health Asset Management, LLC
13F Reported Value
ⓘ$2.1B
incl. option notional
Equity Holdings
ⓘ$1.9B
Option Notional
ⓘ$201.0M
$72.9M puts / $128.1M calls
Holdings
90
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Integral Health Asset Management, LLC disclosed 90 positions worth $2.1B in its Form 13F-HR for Q1 2026 — $1.9B in common stock plus $201.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $INSM (INSMED Inc) at 13.0% of the equity portfolio, followed by $RVMD and $CYTK. During the quarter the fund opened 29 new positions and exited 25 — including a new stake in $RVMD and a full exit from $MDT. The portfolio is most concentrated in Healthcare (96.5% of disclosed assets). All figures are sourced directly from Integral Health Asset Management, LLC’s Form 13F-HR filing with the SEC under CIK 1773206.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 29.4#2,409
Quality
$245.3M1,500,000 sh - —
Quality
$145.9M1,500,000 sh - 28.0#2,453
Quality
$105.5M1,600,000 sh - $72.9M750,000 sh
- 28.0
Quality
$65.9M1,000,000 sh - 75.1
Quality
$65.7M85,000 sh - —
Quality
$64.4M1,600,000 sh - 58.6
Quality
$57.1M270,000 sh - —
Quality
$55.4M2,000,000 sh - 64.3
Quality
$53.3M1,250,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 INSMED Inc$INSM | 29.4#2,409 | $245.3M | 1,500,000 |
 Revolution Medicines, Inc.$RVMD | — | $145.9M | 1,500,000 |
 CYTOKINETICS INC$CYTK | 28.0#2,453 | $105.5M | 1,600,000 |
| Revolution Medicines, Inc.$RVMDPUT | — | $72.9M | 750,000 |
| CYTOKINETICS INC$CYTKCALL | 28.0 | $65.9M | 1,000,000 |
 REGENERON PHARMACEUTICALS, INC.$REGN | 75.1 | $65.7M | 85,000 |
 Vera Therapeutics, Inc.$VERA | — | $64.4M | 1,600,000 |
 CARDINAL HEALTH INC$CAH | 58.6 | $57.1M | 270,000 |
 Roivant Sciences Ltd.$ROIV | — | $55.4M | 2,000,000 |
 BrightSpring Health Services, Inc.$BTSG | 64.3 | $53.3M | 1,250,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Integral Health Asset Management, LLC's 90 positions.
Showing top 10 of 90 holdings.
Sector Allocation
Healthcare
$1.8B
Consumer Staples
$57.1M
Technology
$9.8M
Full Holdings — Integral Health Asset Management, LLC (Q1 2026)
All 90 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $INSM | INSMED Inc | $245.3M | 13.0% | +20% | 29.4 |
| 2 | $RVMD | Revolution Medicines, Inc. | $145.9M | 7.7% | +25% | — |
| 3 | $CYTK | CYTOKINETICS INC | $105.5M | 5.6% | +14% | 28 |
| 4 | $RVMDPUT | Revolution Medicines, Inc. | $72.9M | — | NEW | — |
| 5 | $CYTKCALL | CYTOKINETICS INC | $65.9M | — | +100% | 28 |
| 6 | $REGN | REGENERON PHARMACEUTICALS, INC. | $65.7M | 3.5% | -19% | 75.1 |
| 7 | $VERA | Vera Therapeutics, Inc. | $64.4M | 3.4% | -11% | — |
| 8 | $CAH | CARDINAL HEALTH INC | $57.1M | 3.0% | +35% | 58.6 |
| 9 | $ROIV | Roivant Sciences Ltd. | $55.4M | 2.9% | +135% | — |
| 10 | $BTSG | BrightSpring Health Services, Inc. | $53.3M | 2.8% | +67% | 64.3 |
| 11 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $52.2M | 2.8% | +26% | 30.3 |
| 12 |  $MRK | Merck & Co., Inc. | $51.1M | 2.7% | +70% | 70.9 |
| 13 |  $EWTX | Edgewise Therapeutics, Inc. | $50.4M | 2.7% | +7% | — |
| 14 |  $AZN | ASTRAZENECA PLC | $49.3M | 2.6% | -29% | — |
| 15 | $RVMDCALL | Revolution Medicines, Inc. | $48.6M | — | NEW | — |
| 16 |  $ALHC | Alignment Healthcare, Inc. | $45.4M | 2.4% | +17% | 63 |
| 17 |  $NVS | NOVARTIS AG | $38.2M | 2.0% | +0% | — |
| 18 |  $BSX | BOSTON SCIENTIFIC CORP | $34.5M | 1.8% | +144% | 79.9 |
| 19 |  $LFST | LifeStance Health Group, Inc. | $27.4M | 1.4% | +43% | 53.7 |
| 20 |  $ASND | Ascendis Pharma A/S | $26.3M | 1.4% | +28% | 41.5 |
| 21 |  $SRRK | Scholar Rock Holding Corp | $24.6M | 1.3% | +67% | — |
| 22 |  $ELV | Elevance Health, Inc. | $22.0M | 1.2% | +25% | 59.4 |
| 23 |  $CNC | CENTENE CORP | $21.3M | 1.1% | +0% | 52.7 |
| 24 |  $BBIO | BridgeBio Pharma, Inc. | $20.4M | 1.1% | NEW | 31.7 |
| 25 |  $MLYS | Mineralys Therapeutics, Inc. | $20.3M | 1.1% | +0% | — |
| 26 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $19.8M | 1.1% | +0% | 75.4 |
| 27 |  $GKOS | GLAUKOS Corp | $18.8M | 1.0% | -46% | 39.2 |
| 28 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $18.8M | 1.0% | +200% | 74.4 |
| 29 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $17.9M | 0.9% | NEW | 76.6 |
| 30 |  $ORIC | Oric Pharmaceuticals, Inc. | $17.7M | 0.9% | +17% | — |
| 31 |  $ALMS | ALUMIS INC. | $17.6M | 0.9% | NEW | 9.2 |
| 32 |  $FMS | Fresenius Medical Care AG | $17.5M | 0.9% | +19% | 59.9 |
| 33 |  $ISRG | INTUITIVE SURGICAL INC | $16.1M | 0.8% | -68% | 81.4 |
| 34 |  $QURE | uniQure N.V. | $14.7M | 0.8% | +0% | — |
| 35 |  $TARS | Tarsus Pharmaceuticals, Inc. | $14.0M | 0.7% | +0% | 40.8 |
| 36 |  $GILD | GILEAD SCIENCES, INC. | $13.9M | 0.7% | NEW | 77.8 |
| 37 |  $LLY | ELI LILLY & Co | $13.8M | 0.7% | -25% | 89.3 |
| 38 |  $EW | Edwards Lifesciences Corp | $13.6M | 0.7% | -48% | 67.6 |
| 39 | $MLYSCALL | Mineralys Therapeutics, Inc. | $13.5M | — | +100% | — |
| 40 |  $COGT | Cogent Biosciences, Inc. | $13.5M | 0.7% | NEW | — |
| 41 |  $ELAN | Elanco Animal Health Inc | $13.2M | 0.7% | +120% | 52.2 |
| 42 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $13.1M | 0.7% | NEW | 25.4 |
| 43 |  $PRAX | Praxis Precision Medicines, Inc. | $12.9M | 0.7% | +0% | — |
| 44 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $12.6M | 0.7% | -45% | 26.8 |
| 45 |  $RGNX | REGENXBIO Inc. | $12.6M | 0.7% | +25% | 26.9 |
| 46 |  $DGX | QUEST DIAGNOSTICS INC | $11.8M | 0.6% | -20% | 69.1 |
| 47 |  $XENE | Xenon Pharmaceuticals Inc. | $11.6M | 0.6% | NEW | 12.9 |
| 48 |  $ERAS | Erasca, Inc. | $11.3M | 0.6% | NEW | — |
| 49 |  $ANRO | Alto Neuroscience, Inc. | $11.2M | 0.6% | +33% | — |
| 50 |  $BIIB | BIOGEN INC. | $11.0M | 0.6% | -40% | 65.6 |
| 51 |  $DXCM | DEXCOM INC | $11.0M | 0.6% | -65% | 77.9 |
| 52 |  $SLNO | SOLENO THERAPEUTICS INC | $10.9M | 0.6% | +0% | 46.3 |
| 53 |  $IRON | Disc Medicine, Inc. | $10.9M | 0.6% | NEW | — |
| 54 |  $NRIX | Nurix Therapeutics, Inc. | $10.8M | 0.6% | +133% | 13.2 |
| 55 |  $CVS | CVS HEALTH Corp | $10.8M | 0.6% | -70% | 51.3 |
| 56 |  $COO | COOPER COMPANIES, INC. | $10.7M | 0.6% | -54% | 55.8 |
| 57 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $9.8M | 0.5% | NEW | 63.7 |
| 58 |  $LIVN | LivaNova PLC | $9.5M | 0.5% | NEW | — |
| 59 |  $LNTH | Lantheus Holdings, Inc. | $9.5M | 0.5% | +25% | 66.9 |
| 60 |  $TNGX | Tango Therapeutics, Inc. | $9.4M | 0.5% | +125% | 26.9 |
| 61 |  $IONS | IONIS PHARMACEUTICALS INC | $9.4M | 0.5% | NEW | 37.1 |
| 62 |  $SANA | Sana Biotechnology, Inc. | $9.2M | 0.5% | +7% | — |
| 63 |  $CELC | Celcuity Inc. | $9.1M | 0.5% | +0% | — |
| 64 |  $TARA | Protara Therapeutics, Inc. | $9.1M | 0.5% | -22% | — |
| 65 |  $NVST | Envista Holdings Corp | $8.9M | 0.5% | -30% | 49.8 |
| 66 |  $BHVN | Biohaven Ltd. | $8.5M | 0.5% | -33% | — |
| 67 |  $SNDX | Syndax Pharmaceuticals Inc | $8.2M | 0.4% | +75% | 30 |
| 68 |  $VKTX | Viking Therapeutics, Inc. | $8.1M | 0.4% | +150% | — |
| 69 |  $DFTX | Definium Therapeutics, Inc. | $7.6M | 0.4% | NEW | — |
| 70 |  $BEAM | Beam Therapeutics Inc. | $7.1M | 0.4% | -45% | 12.1 |
| 71 |  $RZLT | Rezolute, Inc. | $6.1M | 0.3% | +0% | — |
| 72 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $6.1M | 0.3% | NEW | — |
| 73 |  $IQV | IQVIA HOLDINGS INC. | $6.0M | 0.3% | NEW | 59.7 |
| 74 |  $AXSM | Axsome Therapeutics, Inc. | $5.9M | 0.3% | NEW | 36.6 |
| 75 |  $PTGX | Protagonist Therapeutics, Inc | $5.3M | 0.3% | NEW | 24.8 |
| 76 |  $EVMN | Evommune, Inc. | $5.2M | 0.3% | +80% | — |
| 77 |  $ACHC | Acadia Healthcare Company, Inc. | $4.7M | 0.3% | NEW | 49.3 |
| 78 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $4.5M | 0.2% | NEW | 64.9 |
| 79 |  $FBRX | Forte Biosciences, Inc. | $3.9M | 0.2% | NEW | — |
| 80 |  $LBRX | LB PHARMACEUTICALS INC | $3.7M | 0.2% | +50% | — |
| 81 |  $SVRA | Savara Inc | $3.3M | 0.2% | NEW | — |
| 82 |  $RLMD | RELMADA THERAPEUTICS, INC. | $3.1M | 0.2% | NEW | — |
| 83 |  $IMCR | Immunocore Holdings plc | $3.0M | 0.2% | NEW | — |
| 84 |  $MAZE | Maze Therapeutics, Inc. | $3.0M | 0.2% | +0% | 19.7 |
| 85 |  $TENX | TENAX THERAPEUTICS, INC. | $2.7M | 0.1% | +0% | — |
| 86 |  $IKT | Inhibikase Therapeutics, Inc. | $2.3M | 0.1% | -23% | — |
| 87 |  $OLMA | Olema Pharmaceuticals, Inc. | $2.2M | 0.1% | NEW | — |
| 88 |  $IVA | Inventiva S.A. | $2.2M | 0.1% | NEW | — |
| 89 |  $SION | Sionna Therapeutics, Inc. | $2.0M | 0.1% | NEW | — |
| 90 |  $UNCY | Unicycive Therapeutics, Inc. | $1.5M | 0.1% | NEW | — |
New Positions (29)
$RVMDPUT Revolution Medicines, Inc.$72.9M$RVMDCALL Revolution Medicines, Inc.$48.6M$BBIO BridgeBio Pharma, Inc.$20.4M$VRTX VERTEX PHARMACEUTICALS INC / MA$17.9M$ALMS ALUMIS INC.$17.6M$GILD GILEAD SCIENCES, INC.$13.9M$COGT Cogent Biosciences, Inc.$13.5M$MDGL MADRIGAL PHARMACEUTICALS, INC.$13.1M$XENE Xenon Pharmaceuticals Inc.$11.6M$ERAS Erasca, Inc.$11.3M$IRON Disc Medicine, Inc.$10.9M$TMO THERMO FISHER SCIENTIFIC INC.$9.8M$LIVN LivaNova PLC$9.5M$IONS IONIS PHARMACEUTICALS INC$9.4M$DFTX Definium Therapeutics, Inc.$7.6MExited Positions (25)
$MDT Medtronic plc
$TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
$PEN Penumbra Inc
$TFX TELEFLEX INC
$ALNY ALNYLAM PHARMACEUTICALS, INC.
$IRTC iRhythm Holdings, Inc.
$UPB Upstream Bio, Inc.
$THC TENET HEALTHCARE CORP
$DOCS Doximity, Inc.
$TERN Terns Pharmaceuticals, Inc.
$UNH UNITEDHEALTH GROUP INC
$RDNT RadNet, Inc.
$ACLX Arcellx, Inc.
$EHC Encompass Health Corp
$CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Integral Health Asset Management, LLC including:
Track Integral Health Asset Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Integral Health Asset Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Integral Health Asset Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Integral Health Asset Management, LLC (SEC CIK: 1773206), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Integral Health Asset Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.